Update on recommendations for eligibility of government subsidization of biologic disease-modifying antirheumatic drugs for the treatment of axial spondyloarthritis in Singapore.

导出 LinkOut

翻译打印收藏纠错

作者： Kee Fong,Phang ^[1] ; Manjari,Lahiri ^[1] ; Warren Weng Seng,Fong ^[2] ; Keng Hong,Leong ^[3] ; Ying Ying,Leung ^[4] ; Anita Yee Nah,Lim ^[3] ; Nai Lee,Lui ^[1] ; Mona,Manghani ^[2] ; Teck Choon,Tan ^[5] ; Amelia,Santosa ^[6] ; Melonie Kannamma,Sriranganathan ^[7] ; Ernest,Suresh ^[1] ; Gim Gee,Teng ^[2] ; Peter P,Cheung ^[8]

作者单位： Division of Rheumatology, University Medicine Cluster, National University Health System, Singapore, Singapore. ^[1] Department of Medicine, Yong Loo Lin School of Medicine, Singapore, Singapore. ^[2] Department of Rheumatology and Immunology, Singapore General Hospital, Singapore, Singapore. ^[3] Leong Keng Hong Arthritis and Medical Clinic, Gleneagles Medical Centre, Singapore, Singapore. ^[4] Lui Centre for Arthritis & Rheumatology, Gleneagles Medical Centre, Singapore, Singapore. ^[5] Department of Rheumatology, Allergy and Immunology, Tan Tock Seng Hospital, Singapore, Singapore. ^[6] Department of Medicine, Khoo Teck Puat Hospital, Singapore, Singapore. ^[7] Department of Medicine, Changi General Hospital, Singapore, Singapore. ^[8] Department General Medicine and Acute Medicine, Ng Teng Fong Hospital, Singapore, Singapore. ^[9]

关键词 IL17 inhibitors ankylosing spondylitis anti-TNF axial spondyloarthritis biologics consensus government recommendation spondyloarthritis subsidy